Nikhil Prasad Fact checked by:Thailand Medical News Team Jan 28, 2025 1 day, 16 hours, 28 minutes ago
Medical News: Study Explores Timing of Corticosteroid Use
A recent study conducted by researchers from Bellvitge University Hospital and Parc Sanitari Hospital del Mar in Barcelona, Spain, has raised critical questions about the timing of immunosuppressive treatments, specifically corticosteroids, in patients with COVID-19. The research aimed to clarify whether the initiation of corticosteroid therapy should depend on the degree of inflammation or the time elapsed since the onset of symptoms.
When to Start Immunosuppressive Treatment for COVID-19?
Corticosteroids like dexamethasone have been a cornerstone in managing severe COVID-19 cases since the landmark RECOVERY trial demonstrated their ability to reduce mortality. However, the optimal timing for initiating these treatments remains uncertain. The study investigated the effects of starting corticosteroids either within the first week of symptom onset or during the second week, focusing on inflammation levels and patient outcomes. This
Medical News report dives deeper into the findings and their implications for clinical practice.
Understanding the Study Design
The study analyzed data from 581 patients admitted to Bellvitge University Hospital between March 2020 and April 2021. All patients were diagnosed with COVID-19 and received a standard dose of dexamethasone (6 mg daily for 10 days). They were divided into two groups: those who started corticosteroid treatment within the first week of symptom onset and those who began treatment between days 8 and 14. Researchers also considered various indicators of inflammation, such as C-reactive protein (CRP), ferritin, and D-dimer levels.
The study's primary outcome was in-hospital mortality, with secondary outcomes including the need for intensive care, mechanical ventilation, or other supportive therapies. Statistical methods, including propensity score matching, were used to ensure comparability between the two groups.
Key Findings on Timing and Outcomes
The study revealed several critical findings. Patients who received corticosteroids within the first week had higher in-hospital mortality rates (29%) compared to those who began treatment in the second week (12.8%). These early-treated patients were also more likely to require invasive mechanical ventilation and intensive care unit (ICU) admission.
However, when researchers adjusted for the degree of inflammation, the timing of corticosteroid initiation did not show a statistically significant effect on mortality. For patients with lower levels of inflammation, starting corticosteroids early appeared to be less beneficial and potentially harmful. On the other hand, for those with high inflammation levels, early treatment did not negatively impact outcomes.
The Role of Inflammation in Treatment Decisions
The study underscores the importance of tailoring corticosteroid therapy to individual patient characteristics, particularly the degree of inflammation. Patients with high inflammation markers, such as elevated CRP and fer
ritin levels, may benefit from early corticosteroid treatment, even during the viral phase of COVID-19. Conversely, initiating treatment too early in patients with lower inflammation levels could lead to worse outcomes.
These findings align with previous research suggesting that the benefits of corticosteroids depend on the patient's inflammatory state. The study highlights the need for clinicians to assess inflammation markers and other risk factors before deciding on the timing of corticosteroid therapy.
Implications for Clinical Practice
The results of this study have significant implications for the management of COVID-19. They suggest that the decision to start corticosteroids should not be based solely on the time elapsed since symptom onset. Instead, clinicians should consider the patient's degree of inflammation and overall clinical condition.
For patients with severe inflammation, delaying corticosteroid treatment could worsen outcomes. On the other hand, for those in the early stages of COVID-19 with mild inflammation, other treatment options may be more appropriate.
Study Strengths and Limitations
This study's strengths include its large, well-characterized cohort and detailed analysis of inflammation markers. However, the researchers acknowledge several limitations, such as the retrospective design and potential biases in patient selection. Additionally, the study did not account for the effects of vaccination, as most patients were treated before widespread vaccine availability.
Conclusion
This study emphasizes the need for a nuanced approach to corticosteroid therapy in COVID-19. While early corticosteroid treatment may not be universally harmful, its benefits depend heavily on the patient's inflammatory state. These findings encourage a more personalized approach to treatment, focusing on individual risk factors rather than rigid timelines.
The study findings were published in the peer-reviewed journal: Medicina.
https://www.mdpi.com/1648-9144/61/2/233
For the latest COVID-19 News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/thailand-medical-study-finds-that-treating-covid-19-patients-with-corticosteroids-increases-risk-of-tuberculosis
https://www.thailandmedical.news/news/covid-19-drugs-french-study-shows-that-corticosteroids-increases-survival-rates-of-elderly-severe-covid-19-patients
https://www.thailandmedical.news/news/glucocorticosteroids-found-to-exacerbate-hmpv-infections-especially-in-those-with-copd